INT242945

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.75
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 9
Disease Relevance 4.57
Pain Relevance 1.28

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (PDE5A) signal transduction (PDE5A) cellular_component (PDE5A)
Anatomy Link Frequency
smooth muscle 1
platelets 1
nervous system 1
kidney 1
PDE5A (Homo sapiens)
Pain Link Frequency Relevance Heat
Central nervous system 67 96.84 Very High Very High Very High
Pain 17 94.24 High High
Multiple sclerosis 35 93.96 High High
nud 10 91.08 High High
headache 18 90.64 High High
Angina 15 75.48 Quite High
Neuropathic pain 5 70.16 Quite High
Inflammation 22 63.32 Quite High
Opioid 5 59.44 Quite High
Neurotransmitter 35 59.20 Quite High
Disease Link Frequency Relevance Heat
Neurological Disease 20 99.16 Very High Very High Very High
Erectile Dysfunction 70 98.40 Very High Very High Very High
Hypertension 37 98.16 Very High Very High Very High
Amnesia 15 94.92 High High
Pain 16 94.24 High High
Demyelinating Disease 35 93.96 High High
Disease 117 91.72 High High
Myalgia 3 91.44 High High
Dyspepsia 10 91.08 High High
Cardiovascular Disease 11 90.96 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Princeton guidelines on use of PDE5i
Localization (use) of PDE5i
1) Confidence 0.75 Published 2006 Journal Clinical Interventions in Aging Section Body Doc Link PMC2699643 Disease Relevance 0.94 Pain Relevance 0.15
Immunohistochemical demonstration of Phosphodiesterase-5
Localization (demonstration) of Phosphodiesterase-5
2) Confidence 0.73 Published 2009 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2680410 Disease Relevance 0 Pain Relevance 0
PDE5 has a typical cytosolic localization with high levels in smooth muscle, platelets, kidney and in some zones of the CNS (Francis and Corbin 1999; Kotera et al 2000; van Staveren et al 2004; Dolci et al 2006; Menniti et al 2006).


Localization (localization) of PDE5 in platelets associated with central nervous system
3) Confidence 0.62 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2518390 Disease Relevance 0.06 Pain Relevance 0.14
Reported PDE5 inhibitors can be divided into the following classes: 1) cGMP-based, represented by sildenafil (Viagra) and vardenafil (Levitra) (Pfizer, Bayer, Sheering-Plough), 2) ?
Localization (Reported) of PDE5
4) Confidence 0.62 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2518390 Disease Relevance 0.98 Pain Relevance 0.26
Use of PDE5 inhibitors in other nervous system diseases
Localization (Use) of PDE5 in nervous system associated with neurological disease
5) Confidence 0.62 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2518390 Disease Relevance 0.91 Pain Relevance 0.33
In 2008, approximately 10 years after the release of the first commercially available PDE5I, a paradigm shift in the management of ED occurred with the approval of once-daily dose of tadalafil by the US Food and Drug Administration for the management of ED.
Localization (release) of PDE5I associated with erectile dysfunction
6) Confidence 0.34 Published 2010 Journal Drug Design, Development and Therapy Section Abstract Doc Link PMC2939761 Disease Relevance 0.94 Pain Relevance 0.14
PDE5 has a typical cytosolic localization with high levels in smooth muscle, platelets, kidney and in some zones of the CNS (Francis and Corbin 1999; Kotera et al 2000; van Staveren et al 2004; Dolci et al 2006; Menniti et al 2006).


Localization (localization) of PDE5 in smooth muscle associated with central nervous system
7) Confidence 0.21 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2518390 Disease Relevance 0.06 Pain Relevance 0.14
PDE5 has a typical cytosolic localization with high levels in smooth muscle, platelets, kidney and in some zones of the CNS (Francis and Corbin 1999; Kotera et al 2000; van Staveren et al 2004; Dolci et al 2006; Menniti et al 2006).


Localization (localization) of PDE5 in kidney associated with central nervous system
8) Confidence 0.21 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2518390 Disease Relevance 0.06 Pain Relevance 0.14
Current US labeling for sildenafil, tadalafil, and vardenafil states that these phosphodiesterase type 5 inhibitors should be started at the lowest recommended dose for patients stabilized on ?
Localization (started) of phosphodiesterase type 5
9) Confidence 0.06 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682383 Disease Relevance 0.64 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox